Here are the latest publicly reported recalls of antidepressants I can confirm right now.
Duloxetine (Cymbalta) recalls in 2024–2026: There were multiple recalls involving duloxetine delayed-release capsules due to impurities potentially linked to nitrosamines and related cancer-risk concerns. Several articles note thousands of bottles affected, with some recalls dating from October 2024 and updates through late 2024; subsequent European and UK notices referenced manufacturing issues or mispackaging in 2026. If you or someone you know is taking duloxetine, check your lot numbers and expiration dates against the FDA/EMA/UK MHRA recall notices and contact a healthcare provider if you’re unsure.[1][4][5][8]
UK and Europe manufacturing recalls in 2026: The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and related bodies issued precautionary recalls for a batch of an antidepressant due to a packaging/manufacturing error, with thousands of packs affected and guidance for pharmacies to stop supply and notify patients. This highlights ongoing vigilance around manufacturing quality in antidepressants.[7][8]
Other sources from late 2024 to 2026: A mix of recall notices and news summaries have covered broader antidepressant recalls tied to impurities or packaging mistakes, including reports from outlets like CNET, Yahoo, and Public Health policy outlets. The common thread is safety-focused recalls, often involving duloxetine or other SSRIs/SNRIs, and guidance to patients to consult clinicians before stopping medication.[2][5][6][1]
What to do if you’re concerned
If you’d like, I can pull the most recent official recall notices for your country (United States or United Kingdom) and extract the exact lot numbers and expiration dates relevant to you. I can also summarize the current status and any recommended patient actions in a quick-reference checklist.
The Medicines and Healthcare products Regulatory Agency (MHRA) has recalled a batch of a commonly prescribed antidepressant as a precautionary measure after an error at the manufacturing site led to the wrong drug being included in a pack. In a class two recall notice published on 28 April 2026, the MHRA said that a pack of […]
pharmaceutical-journal.comBy Children’s Health Defense Team
publichealthpolicyjournal.comThe FDA recalled delayed-release capsules of duloxetine because they potentially contain nitrosamine impurities, which can be harmful with too much exposure.
www.cnet.comThe Food and Drug Administration has recalled Duloxetine, a commonly prescribed antidepressant, due to fears it could contain cancer-causing chemicals.
en.as.comThe UK health watchdog MHRA issued a recall for a commonly prescribed antidepressant across the UK.The recall comes after a patient found the wrong drug inside their sealed packaging.More than 80,000 packs of a popular...
www.geo.tvWhat to know about the product.
www.miamiherald.comPharmaceuticals and wholesalers must return units of affected lots of a recognized antidepressant. The recall does not involve immediate life-threatening risks. Pharmacies and wholesalers must return units of affected lots of a recognized antidepressant. The recall does not involve immediate life-threatening risk.
lavozdeibiza.comThe MHRA has advised healthcare professionals to stop supplying the affected batch of Sertraline 100mg and return all remaining stock to their suppliers.
www.gov.ukThe Defender’s Big Pharma Watch delivers the latest headlines related to pharmaceutical companies and their products, including vaccines, drugs, and medical devices and treatments. The views expressed in the below excerpts from other news sources do not necessarily reflect the views of The Defender. Our goal is to provide readers with breaking news that affects human health and the environment.
childrenshealthdefense.org